- Elyes joined Andera Partners in 2018 as an analyst in the Andera Life Sciences team. He is now Investment Director.
- Prior to joining Andera, Elyes gained a wide range of experience in the pharmaceutical industry (LFB, AstraZeneca).
- Elyes graduated from the Faculty of Pharmacy of the University of Paris-Sud and ESCP.
- He speaks Tunisian, French and English.
Investments of Elyes
Inventiva
Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis
SciRhom
Biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies
Nouscom
Clinical stage immuno-oncology company
Abivax
Clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA
Imcheck
New generation of antibody-based immunotherapy for the treatment of cancer and autoimmune diseases
Erytech
Novel enzymatic therapy for solid and liquid tumours
Corvidia Therapeutics
Antibodies for the treatment inflammation in renal failure
Atlantic Therapeutics
Electrostimulation device for stress incontinence
MedDay Pharmaceuticals
Small molecule for the treatment of progressive multiple sclerosis
Complix
Platform of scaffold proteins oriented against intracellular targets in oncology
Allecra
Development of novel treatments to combat multi drug-resistant bacterial infections
The team andera Life Sciences
Raphaël Wisniewski
Partner
Olivier Litzka
Partner
Sofia Ioannidou
Partner
Jan Van den Bossche
Partner
Aneta Sottil
Partner
Mathieu Piéronne
Director
Yuexin Yu
Director
Natali Romero Barrios
Investment Manager
Yanis Feraoun
Analyst
Elyes Chouaieb
Investment Director
Loan Hoang-Sayag
Venture Partner
Florian Gerard-Mercier
Investment Manager
Thierry Hercend
Venture Partner
Armelle Okoye
Middle Office
Hans J. Moebius
Venture Advisor
Raymond W. Cohen
Venture Advisor
Vanessa Bonvalot
Executive Assistant